JP2005532988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532988A5 JP2005532988A5 JP2003546837A JP2003546837A JP2005532988A5 JP 2005532988 A5 JP2005532988 A5 JP 2005532988A5 JP 2003546837 A JP2003546837 A JP 2003546837A JP 2003546837 A JP2003546837 A JP 2003546837A JP 2005532988 A5 JP2005532988 A5 JP 2005532988A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- itf
- seq
- lesion
- result
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 34
- 239000000203 mixture Substances 0.000 claims 22
- 102000014456 Trefoil Factor-3 Human genes 0.000 claims 14
- 108010078184 Trefoil Factor-3 Proteins 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 10
- 102000007641 Trefoil Factors Human genes 0.000 claims 9
- 108010007389 Trefoil Factors Proteins 0.000 claims 9
- 230000003902 lesion Effects 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims 6
- 239000000812 cholinergic antagonist Substances 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 230000001387 anti-histamine Effects 0.000 claims 4
- 239000000739 antihistaminic agent Substances 0.000 claims 4
- 239000003862 glucocorticoid Substances 0.000 claims 4
- -1 lefecoxib Chemical compound 0.000 claims 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 4
- 229960000707 tobramycin Drugs 0.000 claims 4
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims 2
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 2
- 229930182566 Gentamicin Natural products 0.000 claims 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 2
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 claims 2
- 229930193140 Neomycin Natural products 0.000 claims 2
- 229940122540 Neurokinin receptor antagonist Drugs 0.000 claims 2
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 claims 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 2
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical group CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 2
- 229960004821 amikacin Drugs 0.000 claims 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 2
- 230000002921 anti-spasmodic effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 229940092705 beclomethasone Drugs 0.000 claims 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 2
- 229940124630 bronchodilator Drugs 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- 229960001803 cetirizine Drugs 0.000 claims 2
- 229960000265 cromoglicic acid Drugs 0.000 claims 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 2
- 239000000850 decongestant Substances 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 2
- 229960000520 diphenhydramine Drugs 0.000 claims 2
- 229960005139 epinephrine Drugs 0.000 claims 2
- 229960001022 fenoterol Drugs 0.000 claims 2
- 229960003592 fexofenadine Drugs 0.000 claims 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 2
- 229960000676 flunisolide Drugs 0.000 claims 2
- 229960002714 fluticasone Drugs 0.000 claims 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 2
- 229960002848 formoterol Drugs 0.000 claims 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 2
- 229960002518 gentamicin Drugs 0.000 claims 2
- 229960001680 ibuprofen Drugs 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 229960001361 ipratropium bromide Drugs 0.000 claims 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical group O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims 2
- 229960001268 isoetarine Drugs 0.000 claims 2
- 229940039009 isoproterenol Drugs 0.000 claims 2
- 229960000318 kanamycin Drugs 0.000 claims 2
- 229930027917 kanamycin Natural products 0.000 claims 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 2
- 229930182823 kanamycin A Natural products 0.000 claims 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 2
- 229960003088 loratadine Drugs 0.000 claims 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims 2
- 229960004398 nedocromil Drugs 0.000 claims 2
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims 2
- 229960004927 neomycin Drugs 0.000 claims 2
- 229960000808 netilmicin Drugs 0.000 claims 2
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229960002657 orciprenaline Drugs 0.000 claims 2
- 229960001914 paromomycin Drugs 0.000 claims 2
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 claims 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 229960005205 prednisolone Drugs 0.000 claims 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 2
- 229960002288 procaterol Drugs 0.000 claims 2
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 2
- 229950003941 racepinefrine Drugs 0.000 claims 2
- 229960002052 salbutamol Drugs 0.000 claims 2
- 229960004017 salmeterol Drugs 0.000 claims 2
- 229960005322 streptomycin Drugs 0.000 claims 2
- 239000002462 tachykinin receptor antagonist Substances 0.000 claims 2
- 229960001967 tacrolimus Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- 229960000195 terbutaline Drugs 0.000 claims 2
- 229960000257 tiotropium bromide Drugs 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 229960005294 triamcinolone Drugs 0.000 claims 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 230000009841 epithelial lesion Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000002639 hyperbaric oxygen therapy Methods 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000013618 particulate matter Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 239000000779 smoke Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002627 tracheal intubation Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33383601P | 2001-11-28 | 2001-11-28 | |
| PCT/US2002/038258 WO2003045332A2 (en) | 2001-11-28 | 2002-11-27 | Methods and compositions for treating lesions of the respiratory epithelium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005532988A JP2005532988A (ja) | 2005-11-04 |
| JP2005532988A5 true JP2005532988A5 (https=) | 2006-01-19 |
Family
ID=23304463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003546837A Pending JP2005532988A (ja) | 2001-11-28 | 2002-11-27 | 呼吸上皮の病変を治療するための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20030114384A1 (https=) |
| EP (1) | EP1461076A4 (https=) |
| JP (1) | JP2005532988A (https=) |
| CN (1) | CN1617739A (https=) |
| AU (1) | AU2002351181B2 (https=) |
| CA (1) | CA2468344A1 (https=) |
| MX (1) | MXPA04005053A (https=) |
| WO (1) | WO2003045332A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6525018B1 (en) * | 1999-05-17 | 2003-02-25 | The General Hospital Corp. | Treating eye disorders using intestinal trefoil proteins |
| US20030186882A1 (en) * | 2001-07-31 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating and preventing distal bowel lesions |
| US20030185838A1 (en) * | 2001-11-28 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating lesions of the respiratory epithelium |
| US7654998B1 (en) | 1999-08-23 | 2010-02-02 | Aeris Therapeutics, Inc. | Tissue volume reduction |
| US6610043B1 (en) | 1999-08-23 | 2003-08-26 | Bistech, Inc. | Tissue volume reduction |
| US7538082B2 (en) | 2001-04-24 | 2009-05-26 | The General Hospital Corporation | Methods and compositions for treating oral and esophageal lesions |
| US20040171544A1 (en) * | 2001-04-24 | 2004-09-02 | Barker Nicholas P. | Trefoil domain-containing polypeptides and uses thereof |
| US20030105016A1 (en) * | 2001-09-06 | 2003-06-05 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| US20060189526A1 (en) * | 2002-04-24 | 2006-08-24 | Podolsky Daniel K | Compositions containing an intestinal trefoil peptide and a mucoadhesive |
| US20030181384A1 (en) * | 2001-09-06 | 2003-09-25 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| US20030185839A1 (en) * | 2001-10-05 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating dermal lesions |
| WO2003030824A2 (en) * | 2001-10-05 | 2003-04-17 | The General Hospital Corporation | Methods and compositions for treating dermal lesions |
| RU2004130293A (ru) * | 2002-03-11 | 2005-04-20 | Аэрис Терапьютикс, Инк. (Us) | Способы и композиции для лечения эмфиземы |
| CN1655675A (zh) * | 2002-03-26 | 2005-08-17 | 综合医院公司 | 利用三叶肽的联合治疗 |
| US20060188471A1 (en) * | 2002-10-31 | 2006-08-24 | Podolsky Daniel K | Methods of treating epithelial lesions |
| US20040209806A1 (en) * | 2003-01-17 | 2004-10-21 | Children's Hospital Medical Center | Regulation of allergen induced gene |
| JP2007531743A (ja) * | 2004-04-05 | 2007-11-08 | セプラコア インコーポレーテッド | 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール |
| US8075771B2 (en) * | 2005-02-17 | 2011-12-13 | E. I. Du Pont De Nemours And Company | Apparatus for magnetic field gradient enhanced centrifugation |
| US20100144646A1 (en) * | 2006-11-03 | 2010-06-10 | Blake Paterson | Method of diagnosing and treating asthma |
| CA2678455C (en) * | 2007-01-10 | 2019-02-12 | Board Of Regents The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
| US20110201543A1 (en) * | 2007-06-29 | 2011-08-18 | Blake Paterson | Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress |
| US20100028266A1 (en) * | 2008-08-01 | 2010-02-04 | Alpha Synergy Development. Inc. | Composition and methods for treating allergic response |
| WO2011150944A1 (en) * | 2010-06-04 | 2011-12-08 | Trifoilium Aps | Trefoil factors (tff) for the treatment of chronic pulmonary diseases |
| CN105582526B (zh) * | 2016-02-25 | 2020-07-17 | 山东睿鹰制药集团有限公司 | 三叶因子2在制备治疗及预防肺/支气管急性炎症疾病药物方面的应用 |
| US20230173028A1 (en) * | 2020-03-30 | 2023-06-08 | Shandong Ruiying Pioneer Pharmaceutical Co., Ltd | Application of TFF2 Protein and IFN-k Protein Combination in Treatment of a Novel Coronavirus Infection |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
| US4370317A (en) * | 1980-09-10 | 1983-01-25 | Novo Industri A/S | Pancreatic spasmolytic polypeptide |
| AU1415892A (en) * | 1991-02-14 | 1992-09-15 | General Hospital Corporation, The | Intestinal trefoil proteins |
| US6221840B1 (en) * | 1991-02-14 | 2001-04-24 | The General Hospital Corporation | Intestinal trefoil proteins |
| US6063755A (en) * | 1991-02-14 | 2000-05-16 | The General Hospital Corporation | Intestinal trefoil proteins |
| DK6893D0 (da) * | 1993-01-21 | 1993-01-21 | Novo Nordisk As | Peptid |
| US5563046A (en) * | 1993-08-02 | 1996-10-08 | Celtrix Pharmaceuticals, Inc. | Fusion polypeptides and proteins |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US6426404B1 (en) * | 1997-08-25 | 2002-07-30 | The General Hospital Corporation | Receptor for intestinal trefoil factor |
| JP2002523452A (ja) * | 1998-08-26 | 2002-07-30 | スミスクライン・ビーチャム・コーポレイション | 肺疾患の治療方法 |
| US6372439B2 (en) * | 1998-10-01 | 2002-04-16 | James R. Goldenring | Screen for gastric adenocarcinoma |
| AU2590201A (en) * | 1999-12-23 | 2001-07-03 | Human Genome Sciences, Inc. | Trefoil domain-containing polynucleotides, polypeptides, and antibodies |
| AU2002221565A1 (en) * | 2000-12-08 | 2002-06-18 | Novo-Nordisk A/S | Trefoil factor 2 (tff2) peptides with moiety attached to asn15 |
| CA2444885A1 (en) * | 2001-04-24 | 2002-10-31 | The General Hospital Corporation | Methods and compositions for treating oral and esophageal lesions |
-
2002
- 2002-11-27 JP JP2003546837A patent/JP2005532988A/ja active Pending
- 2002-11-27 US US10/305,747 patent/US20030114384A1/en not_active Abandoned
- 2002-11-27 CN CNA02827590XA patent/CN1617739A/zh active Pending
- 2002-11-27 WO PCT/US2002/038258 patent/WO2003045332A2/en not_active Ceased
- 2002-11-27 CA CA002468344A patent/CA2468344A1/en not_active Abandoned
- 2002-11-27 MX MXPA04005053A patent/MXPA04005053A/es not_active Application Discontinuation
- 2002-11-27 AU AU2002351181A patent/AU2002351181B2/en not_active Ceased
- 2002-11-27 EP EP02786828A patent/EP1461076A4/en not_active Withdrawn
-
2007
- 2007-06-21 US US11/821,367 patent/US20080167230A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532988A5 (https=) | ||
| US20080167230A1 (en) | Methods and compositions for treating or preventing lesions of the respiratory epithelium | |
| Anderson | Delivery options and devices for aerosolized therapeutics | |
| CN1338928A (zh) | 福莫特罗和噻托铵盐的联合形式 | |
| JP2004521950A5 (https=) | ||
| Kaur et al. | Advanced aerosol delivery devices for potential cure of acute and chronic diseases | |
| EP1244487B1 (en) | Aerosol inhaler | |
| US7431916B2 (en) | Administration of medicinal dry powders | |
| CA2558212A1 (en) | Interferon-beta for anti-virus therapy for respiratory diseases | |
| CN101312721A (zh) | 包含格隆铵盐的有机化合物 | |
| US20140342001A1 (en) | Medicaments | |
| US20040101482A1 (en) | Medicaments | |
| US20130125882A1 (en) | Method and composition for treating asthma and copd | |
| Newhouse | Advantages of pressurized canister metered dose inhalers | |
| Ernst | Inhaled drug delivery: a practical guide to prescribing inhaler devices | |
| Roche et al. | Ambulatory inhalation therapy in obstructive lung diseases | |
| Everard et al. | In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system. | |
| US20040258624A1 (en) | Combined doses | |
| TW201016215A (en) | Compositions and uses of antiviral active pharmaceutical agents | |
| Mishra | Delivery of Inhaled Medication in Children: Revisiting Pharmacological and Practical Issues for Better Health Outcome | |
| Martini et al. | Nasal and pulmonary drug delivery systems | |
| Sarkar | Drug Delivery Devices | |
| Mazzaferro | Inhalation therapy: new approaches to old diseases. | |
| SINGH | PULMONARY DRUG DELIVERY SYSTEM: AN OVERVIEW | |
| Shah | AEROSOL BRONCHODILATORS-PRACTICAL CONSIDERATIONS |